Recombinant Human APOC2 protein

中文名： 载脂蛋白C2(APOC2)重组蛋白
别名： APOC2；APC2；Apolipoprotein C-II

货号: PA1000-8817

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	APOC2
Uniprot No	P02655
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	23-101aa
氨基酸序列	TQQPQQDEMPSPTFLTQVKESLSSYWESAKTAAQNLYEKTYLPAVDEKLRDLYSKSTAAMSTYTGIFTDQVLSVLKGEE
预测分子量	10.9 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于APOC2重组蛋白的3篇参考文献示例(注：内容为虚构，仅供格式参考)：

---

1. **文献名称**：Recombinant Human APOC2 Protein: Expression in E. coli and Functional Characterization

**作者**：Smith J et al.

**摘要**：研究报道了通过大肠杆菌系统高效表达重组人APOC2蛋白，并验证其体外激活脂蛋白脂肪酶(LPL)的能力，为相关代谢疾病治疗提供基础。

2. **文献名称**：Role of Recombinant APOC2 in Ameliorating Hypertriglyceridemia in Mouse Models

**作者**：Lee S et al.

**摘要**：通过动物实验证明，注射重组APOC2蛋白可显著降低LPL缺陷小鼠的血清甘油三酯水平，提示其治疗高甘油三酯血症的潜力。

3. **文献名称**：Glycosylation Modulates the Stability and Activity of Recombinant APOC2 Protein

**作者**：Garcia R et al.

**摘要**：比较了不同表达系统(哺乳动物细胞 vs. 原核系统)生产的APOC2重组蛋白，发现糖基化修饰可延长其半衰期并增强LPL激活效率。

---

(实际文献需通过PubMed、Google Scholar等平台检索关键词如"recombinant APOC2"获取。)

背景信息

**Background of Recombinant APOC2 Protein**

Apolipoprotein C-II (APOC2) is a critical component of lipid metabolism, primarily functioning as a coactivator for lipoprotein lipase (LPL), an enzyme responsible for hydrolyzing triglycerides in circulating chylomicrons and very-low-density lipoproteins (VLDL). This process is essential for delivering free fatty acids to peripheral tissues and maintaining plasma lipid homeostasis. Genetic deficiencies in APOC2 lead to hypertriglyceridemia, characterized by severely elevated triglyceride levels, pancreatitis, and increased cardiovascular risk. Traditional therapies for such disorders often focus on dietary management or lipid-lowering agents, but these approaches may not address the root cause in APOC2-deficient patients.

Recombinant APOC2 protein, produced via genetic engineering techniques (e.g., using bacterial or mammalian expression systems), offers a targeted therapeutic strategy. By restoring LPL activation, it enhances triglyceride clearance, potentially mitigating acute and chronic complications of APOC2 deficiency. Beyond hereditary conditions, recombinant APOC2 is also investigated for its role in modulating lipid metabolism in acquired diseases, such as metabolic syndrome and diabetes, where dysfunctional LPL activity contributes to dyslipidemia.

Research further explores its anti-inflammatory and anti-tumor properties, as altered lipid metabolism is linked to cancer progression and immune dysregulation. However, challenges like short plasma half-life and immunogenicity require optimization through protein engineering, such as PEGylation or fusion technologies. Current studies focus on preclinical models and early-phase clinical trials to evaluate efficacy and safety. Overall, recombinant APOC2 represents a promising biologic tool for both therapeutic intervention and mechanistic studies in lipid-related disorders.